Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor
Nancy-Ellen Haynes, Nathan R. Scott, Li C. Chen, Cheryl A. Janson, Jiakui Li, Christine Lukacs, Aruna Railkar, Effie Tozzo, Toni Whittard, Nicholas Fraser Brown, Adrian Wai‐Hing Cheung · ACS Medicinal Chemistry Letters · 2012
3-[4-((1S,2S,3R,5S,7S)-5-Hydroxyadamantan-2-ylcarbamoyl)benzyl]-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester (4) was identified as a novel, druglike and selective quinolone pan JNK inhibitor. In this communication, some of the structure-activity relationship of the azaquinolone analogues leading to 4 is discussed. The focus is on how changes at the amide functionality affected the biochemical potency, cellular potency, metabolic properties, and solubility of this class of JNK inhibitors. Optimization of these properties led to the identification of the adamantyl analogue, 4. 4 achieved proof of mechanism in both rat and mouse TNF-α challenge models.